Inhibition of peroxisome proliferator-activated receptor γ activity suppresses pancreatic cancer cell motility

Cancer Science

Volumn 99, Issue 10, 2008, Pages 1892-1900

  Nakajima, Atsushi ^a   Tomimoto, Ayako ^a   Fujita, Koji ^a   Sugiyama, Michiko ^a   Takahashi, Hirokazu ^a   Ikeda, Ikuko ^a   Hosono, Kunihiro ^a   Endo, Hiroki ^a   Yoneda, Kyoko ^a   Iida, Hiroshi ^a   Inamori, Masahiko ^a   Kubota, Kensuke ^a   Saito, Satoru ^a   Nakajima, Noriko ^b   Wada, Koichiro ^c   Nagashima, Yoji ^d   Nakagama, Hitoshi ^e  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITRO N (4 PYRIDYL)BENZAMIDE; CATENIN; GUANOSINE TRIPHOSPHATASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN CDC42; PROTEIN P120; RAC1 PROTEIN; RAS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL ASSAY; CELL MEMBRANE; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; GENE REPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER METASTASIS; MALE; METASTASIS; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; SCID MOUSE; SEQUENCE HOMOLOGY; XENOGRAFT;

ANIMALS; BENZAMIDES; CDC42 GTP-BINDING PROTEIN; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL MOVEMENT; HUMANS; LIGANDS; MICE; MICE, SCID; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; PHOSPHOPROTEINS; PPAR GAMMA; PYRIDINES; RAC1 GTP-BINDING PROTEIN; RNA, SMALL INTERFERING; THIAZOLIDINEDIONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 54949147269     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00904.x     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
2. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000; 405: 421-4.
3. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649-88.
4. Takashima T, Fujiwara Y, Higuchi K et al. PPAR-γ ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity. Int J Oncol 2001; 19: 465-71.
5. Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res 2000; 60: 1129-38.
6. DuBois RN, Gupta R, Brockman J, Reddy BS, Krakow SL, Lazar MA. The nuclear eicosanoid receptor, PPARγ, is aberrantly expressed in colonic cancers. Carcinogenesis 1998; 19: 49-53.
7. Mueller E, Sarraf P, Tontonoz P et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1998; 1: 465-70.
8. Sato H, Ishihara S, Kawashima K et al. Expression of peroxisome proliferator-activated receptor (PPAR) γ in gastric cancer and inhibitory effects of PPARγ agonists. Br J Cancer 2000; 83: 1394-400.
9. Guan YF, Zhang YH, Breyer RM, Davis L, Breyer MD. Expression of peroxisome proliferator-activated receptor γ (PPARγ) in human transitional bladder cancer and its role in inducing cell death. Neoplasia 1999; 1: 330-9.
10. Kitamura S, Miyazaki Y, Shinomura Y, Kondo S, Kanayama S, Matsuzawa Y. Peroxisome proliferator-activated receptor γ induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res 1999; 90: 75-80.
11. Debrock G, Vanhentenrijk V, Sciot R, Debiec-Rychter M, Oyen R, Van Oosterom A. A phase II trial with rosiglitazone in liposarcoma patients. Br J Cancer 2003; 89: 1409-12.
12. Kulke MH, Demetri GD, Sharpless NE et al. A phase II study of troglitazone, an activator of the PPARγ receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J 2002; 8: 395-9.
13. Martelli ML, Iuliano R, Le Pera I et al. Inhibitory effects of peroxisome poliferator-activated receptor γ on thyroid carcinoma cell growth. J Clin Endocrinol Metab 2002; 87: 4728-35.
14. Panigrahy D, Shen LQ, Kieran MW, Kaipainen A. Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opin Invest Drugs 2003; 12: 1925-37.
15. Posch MG, Zang C, Mueller W, Lass U, von Deimling A, Elstner E. Somatic mutations in peroxisome proliferator-activated receptor-γ are rare events in human cancer cells. Med Sci Monit 2004; 10: BR250-4.
16. Lefebvre AM, Chen I, Desreumaux P et al. Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 1998; 4: 1053-7.
17. Saez E, Tontonoz P, Nelson MC et al. Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nat Med 1998; 4: 1058-61.
18. Kristiansen G, Jacob J, Buckendahl AC et al. Peroxisome proliferator-activated receptor γ is highly expressed in pancreatic cancer and is associated with shorter overall survival times. Clin Cancer Res 2006; 12: 6444-51.
19. Masuda T, Wada K, Nakajima A et al. Critical role of peroxisome proliferator-activated receptor γ on anoikis and invasion of squamous cell carcinoma. Clin Cancer Res 2005; 11: 4012-21.
20. Schaefer KL, Wada K, Takahashi H et al. Peroxisome proliferator-activated receptor γ inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. Cancer Res 2005; 65: 2251-9.
21. Takahashi H, Fujita K, Fujisawa T et al. Inhibition of peroxisome proliferator-activated receptor γ activity in esophageal carcinoma cells results in a drastic decrease of invasive properties. Cancer Sci 2006; 97: 854-60.
22. Lea MA, Sura M, Desbordes C. Inhibition of cell proliferation by potential peroxisome proliferator-activated receptor (PPAR) γ agonists and antagonists. Anticancer Res 2004; 24: 2765-71.
23. Ramilo G, Valverde I, Lago J, Vieites JM, Cabado AG. Cytotoxic effects of BADGE (bisphenol A diglycidyl ether) and BFDGE (bisphenol F diglycidyl ether) on Caco-2 cells in vitro. Arch Toxicol 2006; 80: 748-59.
24. Fritz G, Kaina B. Rho GTPases: Promising cellular targets for novel anticancer drugs. Curr Cancer Drug Targets 2006; 6: 1-14.
25. Taniuchi K, Nakagawa H, Hosokawa M et al. Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating Rho-family GTPases. Cancer Res 2005; 65: 3092-9.
26. Anastasiadis PZ. p120-ctn: A nexus for contextual signaling via Rho GTPases. Biochim Biophys Acta 2007; 1773: 34-46.
27. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 1983; 65: 55-63.
28. Yasui N, Sakamoto M, Ochiai A et al. Tumor growth and metastasis of human colorectal cancer cell lines in SCID mice resemble clinical metastatic behaviors. Invasion Metastasis 1997; 17: 259-69.
29. Nobes CD, Hall A. Rho GTPase control polarity, protrusion, and adhesion during cell movement. J Cell Biol 1999; 144: 1235-44.
30. Noren NK, Liu Bp Burridge K, Kreft B. p120 catenin regulates the actin cytoskeleton via Rho family GTPase. J Cell Biol 2000; 150: 567-80.
31. Nobes CD, Hall A. Rho GTPases control polarity, protrusion, and adhesion during cell movement. J Cell Biol 1999; 144: 1235-44.
32. Noren NK, Liu BP, Burridge K, Kreft B. p120 catenin regulates the actin cytoskeleton via Rho family GTPases. J Cell Biol 2000; 150: 567-80.
33. Anastasiadis PZ, Reynolds AB. Regulation of Rho GTPases by p120-catenin. Curr Opin Cell Biol 2001; 13: 604-10.